Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrilizumab plus apatinib or first-line chemotherapy for advanced hepatocellular carcinoma
ChiCTR2000041446Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000041446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041446.